MYF5 and chronic obstructive pulmonary disease: The treatment significantly alleviated the reduced expression levels of myogenin, Myf5, and myogenic regulatory factor 4 in the muscles of COPD rats, leading to improvements in skeletal muscle atrophy and muscle mass [69].